The Prevalence and Genotype of Human Papillomavirus from Patients with Genital Warts in Eastern Guangdong Province

  • Luo, Zhao-Yun (Central Laboratory, Chaozhou Central Hospital) ;
  • Chen, Qiang (Central Laboratory, Chaozhou Central Hospital) ;
  • Yang, Hui (Central Laboratory, Chaozhou Central Hospital) ;
  • Lin, Min (Central Laboratory, Chaozhou Central Hospital) ;
  • Chen, Chan-Yu (Department of Gynecology and Obstetrics, Chaozhou Central Hospital) ;
  • Yang, Chun (Department of Gynecology and Obstetrics, Chaozhou Central Hospital) ;
  • Yang, Li-Ye (Central Laboratory, Chaozhou Central Hospital)
  • Published : 2015.09.02


Background: Low-risk human papillomavirus (LR-HPV) infection is the main cause of genital warts. LRHPV genotypes 6 and 11 are associated with genital warts, but there have only been a few published studies about the genotype-specific prevalence of HPV in genital warts in China. The objective of our study was to assess the prevalence of HPV genotypes for clinical cases involving both men and women and to evaluate the potential benefit of a quadrivalent (genotypes 6, 11, 16, and 18) HPV vaccine in eastern Guangdong province of China. Materials and Methods: A total of 696 eligible patients with genital warts were enrolled during the period Aug 2009 through Oct 2014. Specimens were collected from genital warts, the HPV GenoArray test was used for HPV detection and genotyping, which could detect 21 HPV genotypes, including genotypes 6, 11, 16, and 18. Results: Among the 696 cases, 675 samples were successfully genotyped. The median age of patients was 32.1 years (range, 16-67 years). The most prevalent genotypes were HPV-6 (285/675, 42.2%), HPV-11 (265/675, 39.3%), HPV-52 (52/675, 7.7%), HPV-16 (51/675, 7.56%), HPV-81 (50/675, 7.40%) and HPV-58 (37/675, 5.48%). Low-risk genotypes predominated, with a prevalence of 96.59%. The cumulative prevalence of genotypes 6 and 11 was 78.7% (531/675), the cumulative prevalence of genotypes 16 and 18 was 11.6% (78/675), and the cumulative prevalence of genotypes 6, 11, 16, and 18 was 82.5% (557/675). Conclusions: Our results provide strong evidence that, in eastern Guangdong, different from Western countries, the most prevalent low risk HPV genotypes in patients with genital warts are 6, 11 and 81. The quadrivalent HPV vaccine could prevent 82.5% of genital warts in eastern Guangdong.


  1. Aubin F, Pretet JL, Jacquard AC, et al (2008). Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis, 47, 610-5.
  2. Bodily J, Laimins LA (2011). Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol, 19, 33-9.
  3. Brown DR, Kjaer SK, Sigurdsson K, et al (2009).The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis, 199, 926-35.
  4. Chan PK, Luk AC, Luk TN, et al (2009). Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol, 44, 111-4.
  5. Chen Q, Xie LX, Qing ZR, et al (2012). Epidemiologic characterization of human papillomavirus infection in rural chaozhou, eastern guangdong province of China. PLoS One, 7, 32149.
  6. Chen Q, Luo ZY, Lin M, et al (2012). Prevalence and genotype distribution of human papillomavirus infections in women attending hospitals in Chaozhou of Guangdong province. Asian Pac J Cancer Prev, 13, 1519-24.
  7. Cremin S, Menton JF, Canier L, Horgan M, Fanning LJ (2012). The prevalence and genotype of human papillomavirus on cervical samples from an Irish female population with external genital warts. Hum Vaccin Immunother, 8, 916-20.
  8. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004). Classification of papillomaviruses. Virol, 324, 17-27.
  9. Huang Y, Lin M, Luo ZY, et al (2013). Low prevalence of HPV in male sexual partners of HR-HPV infected females and low Asian Pac J Cancer Prev, 14, 1755-60.
  10. Johnson AM, Mercer CH, Beddows S, et al (2012). Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect, 88, 212-7.
  11. Li J, Kang LN, Qiao YL (2011). Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev, 12, 1149-53.
  12. Lin M, Yang LY, Li LJ, et al (2008). Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust N Z J Obstet Gynaecol, 48, 189-94.
  13. McCormack PL, Joura EA (2011). Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women. Bio Drugs, 25, 339-43.
  14. Richardson H, Kelsall G, Tellier P, et al (2003). The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev, 12, 485-90.
  15. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  16. Zhao FH, Lewkowitz AK, Hu SY, et al (2012). Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer, 131, 2929-38.